FEB 28, 2019 7:00 AM PST

ELISA-like Assay Formats and the Benefits of Assay Automation

Speaker
  • Scientist IV - Antibody Generation - Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceuticals, Inc.
    Biography
      I attended the University of Connecticut where I received my Bachelors Degree in Physiology/Neurobiology in 1999. I then attended graduate school at Southern Connecticut State University where I earned my Master's Degree in Biology. I have worked at Yale School of Medicine, Perkin Elmer, Thermo Electron, Pfizer and am currently employed at Boehringer Ingelheim Pharmaceuticals. The majority of my expertise is in immunoassay development and validation. I also have extensive experience in lab automation and integration. I served in the US Army as a Medic for 12 years attaining the rank of Staff Sergeant and completing tours of duty in Bosnia in 2001 and Iraq in 2005. My current duties are in overseeing Boehringer's High Throughput Antibody Discovery team, whose principal duties are primary screening, cloning and transient expression of therapeutic antibody candidates.

    Abstract
    DATE:    February 28, 2019
    TIME:    7:00 AM PST, 10:00 AM EST
     
    Bringing automation on any scale into your lab can be an intimidating prospect, especially for new users. There can be significant benefits to automating a method or process, but there are also many factors to consider and even more potential pitfalls. It is a common misconception that automation or integrated platforms have to be big, expensive and complex. There is also a common misconception that less complex assay formats don’t benefit from automation. Implementing automation can be as complex as large, walk-away high-throughput screening platforms or as simple as a plate reader and stacker, or any combination in between. Thoughtful planning and careful implementation are the two factors that determine the overall success of the process.
     
    This webinar will explore the benefits of automating less complex assay formats while also addressing some of the considerations that need to be examined, such as scope, scale and cost. We will focus on ELISA and “ELISA-like” assay formats and provide an example of an existing integration used for MSD-based antibody discovery.
     
     
    Learning objectives:
    • Understanding of the many variants of the classic ELISA assay as well as newer, “ELISA-like” assay formats and the benefits that they bring.
    • Understand key challenges to automating assay methods or entire processes.
     
    LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.

    Show Resources
    You May Also Like
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    NOV 10, 2020 7:00 AM PST
    C.E. CREDITS
    NOV 10, 2020 7:00 AM PST
    DATE: November 10, 2020 TIME: 7:00am PDT, 10:00am EDT Automation can provide tremendous benefits such as increased pipetting precision and accuracy, productivity, and throughput. Numerous wo...
    SEP 03, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 03, 2020 9:00 AM PDT
    DATE: September 3, 2020 TIME: 09:00am PT, 12:00pm ET xxx Learning Objectives: xxx Webinars will be available for unlimited on-demand viewing after live event. LabRoots is approved as a provi...
    JUN 23, 2020 10:00 AM PDT
    C.E. CREDITS
    JUN 23, 2020 10:00 AM PDT
    DATE: June 23, 2020 TIME: 10:00am PT Human mesenchymal stromal or stem cells (MSCs)-based immunomodulation treatment has been proposed as a suitable therapeutic approach for many diseases, s...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    Loading Comments...
    Show Resources
    Attendees
    • See more